OphtiMed Rx
Novel Molecular Treatment for Dry Age-related Macular Degeneration
Health Tech & Life Sciences
Private
Company Overview
Snapshot
Founded in November 2021 by Dana Rabinovich, OphtiMed Rx operates with 1–10 employees. The company has raised $1.3M across one funding round from one investor, G.O Innovation. OphtiMed Rx is developing a novel molecular therapy for dry age-related macular degeneration.
Business overview
OphtiMed Rx is a Health Tech &. The company's core technology aims to protect retinal cells from senescence, thereby halting the progression of dry AMD. Operating within the Pharmaceuticals, Pharma & Medical Biotechnology, and Drugs Discovery & Development sectors, OphtiMed Rx's treatment is designed to prevent vision loss and enhance patient independence.
Company Intelligence Q&A
- What is OphtiMed Rx's primary focus?
- OphtiMed Rx is developing a novel molecular therapy specifically for dry age-related macular degeneration (AMD), a common eye disease that can lead to blindness.
- When was OphtiMed Rx founded?
- OphtiMed Rx was founded in November 2021.
- Who is a co-founder of OphtiMed Rx?
- Dana Rabinovich is a co-founder and CEO of OphtiMed Rx.
- What is the company's main product in development?
- OphtiMed Rx's main product is OM-301, a molecular therapy designed to protect retinal cells from cellular aging and halt the progression of dry AMD.
- What is the total capital raised by OphtiMed Rx?
- OphtiMed Rx has raised a total of $1.3M in funding.